US/UK/Canada

Share

Contacts

  • Bent U. Frandsen

    CEO


    +45 2222 1019
    http://www.expres2ionbio.com
  • Keith Alexander

    CFO


    +45 2222 1019
    http://www.expres2ionbio.com
    • Pick a time period -
    Tags ( Active)

    Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN

    Hørsholm, Denmark, 20 January 2026 – ExpreS2ion Biotech Holding AB’s today announces that, effective today, 20 January 2026, the Company will transition its press release distribution from Cision to MFN (Modular Finance News). Subscribers who wish to continue receiving the Company’s press releases must register on the MFN platform. This change is part of the Company’s ongoing efforts to streamline regulatory news distribution.To continue receiving Expres2ion Biotech Holding’s press releases, including future regulatory announcements, current subscribers of Cision News are required to

    ExpreS2ion to Participate in Key Investor Event in January 2026

    Hørsholm, Denmark, 19 January 2026 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in an upcoming investor event in January 2026, the Redeye Thematic Event: Fight Cancer.These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the Company’s website  and via the links below. To

    ExpreS2ion Reports Updated Immunogenicity Data from First Three Patients and DSMB Recommendation to Progress ES2B-C001 Phase I Trial to Next Dose Cohort

    Hørsholm, Denmark, 19 December 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today reports (i) updated immunogenicity results from the first three patients enrolled in its ongoing Phase I clinical trial of ES2B-C001, a novel HER2-targeted therapeutic breast cancer vaccine, and (ii) that the independent Data Safety Monitoring Board (DSMB) has reviewed safety data from the first cohort and recommended progression to the

    ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 2025

    Hørsholm, Denmark, 13 November 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first nine months and third quarter 2025 results. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments:“ExpreS2ion made solid progress in the third quarter, advancing our clinical and collaborative programs while maintaining financial discipline. The significant HER2-specific antibody responses observed in the first patient in the ongoing Phase I trial of ES2B-C001 marks an encouraging

    Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines

    This press release is a correction to the press release made earlier this afternoon, which did not specify the aggregated milestones as being in EUR millions. Hørsholm, Denmark, 12 November 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today announced the execution of a definitive licensing agreement with Serum Institute of India Pvt. Ltd. (“SII”) for two novel blood-stage malaria vaccines, RH5.1 and R78C. The

    ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines

    Hørsholm, Denmark, 12 November 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today announced the execution of a definitive licensing agreement with Serum Institute of India Pvt. Ltd. (“SII”) for two novel blood-stage malaria vaccines, RH5.1 and R78C. The agreement builds upon the previously announced term sheet 

    Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases

    Hørsholm, Denmark, 10 November 2025 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”), a clinical-stage biotechnology company developing innovative vaccine candidates targeting infectious diseases and cancer, today announces continued clinical progress across several University of Oxford malaria vaccine programs, which apply the ExpreS2 platform. The advancement of these studies continues to support evidence of the platform’s reliability in complex vaccine development and may support future licensing opportunities, consistent with the Company’s announced term-sheet

    ExpreS2ion Hereby Changes Certified Advisor to Redeye

    Hørsholm, Denmark, 7 November 2025 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) today announces it has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on February 1, 2026. Until then, Svensk Kapitalmarknadsgranskning AB will continue as Certified Adviser to the company.Certified AdviserSvensk Kapitalmarknadsgranskning AB

    ExpreS2ion to Participate in Key Investor and Industry Events in November 2025

    Hørsholm, Denmark, 3 November 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in three key upcoming investor events in November 2025: BIO-Europe, the 2025 Interim Report (Q3) Presentation and the BioStock Life Science Summit.These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are available on the Company’s website 

    VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase

    Hørsholm, Denmark, 8 October 2025 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”), a clinical-stage biotechnology company developing innovative vaccine candidates targeting infectious diseases and cancer, today announces that the international VICI-Disease consortium has selected its lead antigen for the Nipah virus (NiV) vaccine project. The chosen antigen, derived from the Nipah virus G protein and coupled to a virus-like particle (VLP), was recently finalized as the vaccine candidate. This milestone marks the transition from discovery to pre-clinical development,

    ExpreS2ion Biotechnologies: Warrants of Series TO 11 Were Exercised to Approximately 88.5 Percent, ExpreS2ion Receives Approximately SEK 10.4 Million and Resolves on Directed Issues to Guarantors

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 6 October 2025 - Today ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces the outcome of the exercise of warrants of series TO 11, which were issued in connection with the Company'

    ExpreS2ion Obtains Top Guarantee Commitments and Subscription Commitments for Warrant Program TO 11, Reflecting Continued Support and Reinforcing Funding

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 15 September 2025 – ExpreS2ion Biotech Holding AB (publ) ("Expres2ion" or the "Company"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious

    ExpreS2ion Announces TO 11 Warrant Exercise Price and Start of Exercise Period

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 12 September 2025 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the exercise price for the warrants of series TO 11 has been determined to SEK 14.65 and that the

    ExpreS2ion to Present in Upcoming Investor Events

    Hørsholm, Denmark, 12 September 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in three key upcoming investor events in September 2025: Aktiespararna Aktiedagarna, the H.C. Andersen Capital Institutional Investor Seminar, and BioStock Investing in Life Science conference.These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information,

    ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial

    Hørsholm, Denmark, 4 September 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer today reports the first immunogenicity results from its ongoing Phase I clinical trial evaluating ES2B-C001, a novel HER2-targeted therapeutic breast cancer vaccine. The data, derived from the first patient enrolled in the trial, indicate that the vaccine is triggering a significant immune response.Early Evidence of Immune Activation The

    ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events

    Hørsholm, Denmark, 2 September 2025 – ExpreS2ion Biotech Holding AB’s (“ExpreS2ion” or the “Company”) CEO, Bent U. Frandsen, recently presented at two investor-focused events: Økonomisk Ugebrev’s Life Science Conference (27 August 2025) and ProHearings’ Life Science Seminar (29 August 2025). These appearances provided an opportunity for the Company to share updates on its breast cancer vaccine candidate ES2B-C001, as well as its broader pipeline and financial position, with a wide audience of investors, analysts, and stakeholders.Event HighlightsAt both events, Mr. Frandsen highlighted:

    ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 75

    Hørsholm, Denmark, 27 August 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) is pleased to announce that Analysguiden has published a new analyst report following the Company’s Q2 2025 results and the dosing of the first patient in its Phase I clinical trial with breast cancer vaccine candidate ES2B-C001. The report reiterates a fair value per share of SEK 75, corresponding to a market capitalization of SEK 475 million, based on risk-adjusted net present value analysis.Key Highlights from the Report · Phase I Trial

    ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 303

    Hørsholm, Denmark, 21 August 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) is pleased to announce that Pareto Securities has published a sponsored research update following the Company’s announcement of Q2 2025 financial results earlier today.Key points from the Pareto Securities note: · ExpreS2ion reported a Q2 ’25 quarter-end cash position of SEK 48.8 million, following a SEK 10 million loss for the period. Pareto regards this as consistent with previous commentary of cash reach into next year. On the Company’s webcast

    ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025

    Hørsholm, Denmark, 21 August 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its half-year and second quarter 2025 results. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments:“In the second quarter, ExpreS2ion achieved key milestones that demonstrate both clinical progress and strategic alignment. The dosing of the first patient in our Phase I breast cancer trial marks a major step in our evolution into a clinical-stage company, supported by regulatory approval of

    ExpreS2ion to Present in Upcoming Investor Events

    Hørsholm, Denmark, 15 August 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in three key upcoming investor events in August 2025: the presentation of Half-Year (Q2) results, Økonomisk Ugebrev’s Life Science Investor Conference, and ProHearings’ Capital Markets Day.These events represent important opportunities to showcase ExpreS2ion’s innovative technology platform and exciting development pipeline to scientific and investment audiences. More details, including event registration information, are

    ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac

    Hørsholm, Denmark, 18 July 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, “ExpreS2ion” or the “Company”), a clinical-stage biotechnology company with a focused portfolio of immunotherapy candidates for infectious diseases and cancer, today acknowledges the announcement by the Global Health Innovative Technology (GHIT) Fund of a new international vaccine development project supported by JPY 800 million (approx. EUR 4.6 million) in funding. The project will develop a novel blood-stage malaria vaccine candidate using the virus-like particle (VLP) platform of

    ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer

    Hørsholm, Denmark, 7 July 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, “ExpreS2ion” or the “Company”), a clinical-stage biotechnology company with a focused portfolio of immunotherapy candidates for infectious diseases and cancer, today announced that it has entered into an Infrastructure-as-a-Service (IaaS) agreement with the Technical University of Denmark (DTU) to gain access to Computerome 2.0, one of Denmark’s most advanced high-performance computing (HPC) platforms for secure biomedical data processing.This agreement enables ExpreS2ion to conduct

    Austrian Regulatory Green Light Enables ADC Combination Testing and Phase I Site Expansion for ES2B-C001, a First-in-Class Breast Cancer Immunotherapy

    Hørsholm, Denmark, 30 June 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, “ExpreS2ion” or the “Company”), a clinical-stage biotechnology company with a focused portfolio of immunotherapy candidates for infectious diseases and cancer, today announced that the Austrian regulatory authorities have approved the Company’s protocol amendment to evaluate its breast cancer immunotherapy candidate, ES2B-C001, in combination with HER2-targeted antibody-drug conjugates (ADCs) and to expand the number of trial sites.Filed on 13 May 2025 

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media